Home/Zentalis Pharmaceuticals/Ingmar Bruns, M.D.

IB

Ingmar Bruns, M.D.

Chief Medical Officer

Zentalis Pharmaceuticals

Therapeutic Areas

Zentalis Pharmaceuticals Pipeline

Drug	Indication	Phase
Azenosertib	Cyclin E1+ Platinum-Resistant Ovarian Cancer (PROC) - Monotherapy	Phase 2

Leadership Team at Zentalis Pharmaceuticals

Chief Executive Officer, President and Director

Chief People Officer

View full Zentalis Pharmaceuticals profile